Ezra Eddy Wyssam Cohen

Ezra Eddy Wyssam Cohen

Auto-generated profile, based on publicly available information

Ezra Eddy Wyssam Cohen

Moores Cancer Center at University of California San Diego, La Jolla, California

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in The Lancet
Verified
Journal Article
Closed access
ECEzra E W Cohen
Ezra E W Cohen
CTChristophe Le Tourneau
Christophe Le Tourneau
LLLisa Licitra
Lisa Licitra
MAMyung-Ju Ahn
Myung-Ju Ahn
ASAinara Soria
Ainara Soria
DZDan Zandberg
Dan Zandberg

19 September 2016 in Nature
Verified
Journal Article
Closed access
PDF file
MKMegan M. Kaneda
Megan M. Kaneda
KMKaren S. Messer
Karen S. Messer
NRNatacha Ralainirina
Natacha Ralainirina
HLHongying Li
Hongying Li
CLChristopher J. Leem
Christopher J. Leem
JVJudith A. Varner
Judith A. Varner

10 October 2013 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
RERosella Elisei
Rosella Elisei
MSMartin J. Schlumberger
Martin J. Schlumberger
SMStefan P. Müller
Stefan P. Müller
PSPatrick Schöffski
Patrick Schöffski
MBMarcia S. Brose
Marcia S. Brose
SSSteven I. Sherman
Steven I. Sherman
Purpose: Cabozantinib, a tyrosine kinase inhibitor (TKI) of hepatocyte growth factor receptor (MET), vascular endothelial growth factor receptor 2, and rearranged during transfection (RET), demonstrated clinical activity in patients with medullary thyroid cancer (MTC) in phase I. Patients and Methods: We conducted a double-blind, phase III trial comparing cabozantinib with placebo in 330 patients with documented radiographic progression of metastatic MTC. Patients were randomly assigned (2:1) to cabozantinib (140 mg per day) or placebo. The primary end point was progression-free survival (PFS). Additional outcome measures included tumor response rate, overall survival, and safety. Results: The estimated median PFS was 11.2 months for cabozantinib versus 4.0 months for placebo (hazard ratio, 0.28; 95% CI, 0.19 to 0.40; P < .001). Prolonged PFS with cabozantinib was observed across all subgroups including by age, prior TKI treatment, and RET mutation status (hereditary or sporadic). Response rate was 28% for cabozantinib and 0% for placebo; responses were seen regardless of RET mutation status. Kaplan-Meier estimates of patients alive and progression-free at 1 year are 47.3% for cabozantinib and 7.2% for placebo. Common cabozantinib-associated adverse events included diarrhea, palmar-plantar erythrodysesthesia, decreased weight and appetite, nausea, and fatigue and resulted in dose reductions in 79% and holds in 65% of patients. Adverse events led to treatment discontinuation in 16% of cabozantinib-treated patients and in 8% of placebo-treated patients. Conclusion: Cabozantinib (140 mg per day) achieved a statistically significant improvement of PFS in patients with progressive metastatic MTC and represents an important new treatment option for patients with this rare disease. This dose of cabozantinib was associated with significant but manageable toxicity.

1 February 2015 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
TSTanguy Y. Seiwert
Tanguy Y. Seiwert
ZZZhixiang Zuo
Zhixiang Zuo
MKMichaela K. Keck
Michaela K. Keck
AKArun Khattri
Arun Khattri
CPChandra S. Pedamallu
Chandra S. Pedamallu
PHPeter S. Hammerman
Peter S. Hammerman
Purpose: The genetic differences between human papilloma virus (HPV)–positive and –negative head and neck squamous cell carcinomas (HNSCC) remain largely unknown. To identify differential biology and novel therapeutic targets for both entities, we determined mutations and copy-number aberrations in a large cohort of locoregionally advanced HNSCC. Experimental Design: We performed massively parallel sequencing of 617 cancer-associated genes in 120 matched tumor/normal samples (42.5% HPV-positive). Mutations and copy-number aberrations were determined and results validated with a secondary method. Results: The overall mutational burden in HPV-negative and HPV-positive HNSCC was similar with an average of 15.2 versus 14.4 somatic exonic mutations in the targeted cancer-associated genes. HPV-negative tumors showed a mutational spectrum concordant with published lung squamous cell carcinoma analyses with enrichment for mutations in TP53, CDKN2A, MLL2, CUL3, NSD1, PIK3CA, and NOTCH genes. HPV-positive tumors showed unique mutations in DDX3X, FGFR2/3 and aberrations in PIK3CA, KRAS, MLL2/3, and NOTCH1 were enriched in HPV-positive tumors. Currently targetable genomic alterations were identified in FGFR1, DDR2, EGFR, FGFR2/3, EPHA2, and PIK3CA. EGFR, CCND1, and FGFR1 amplifications occurred in HPV-negative tumors, whereas 17.6% of HPV-positive tumors harbored mutations in fibroblast growth factor receptor genes (FGFR2/3), including six recurrent FGFR3 S249C mutations. HPV-positive tumors showed a 5.8% incidence of KRAS mutations, and DNA-repair gene aberrations, including 7.8% BRCA1/2 mutations, were identified. Conclusions: The mutational makeup of HPV-positive and HPV-negative HNSCC differs significantly, including targetable genes. HNSCC harbors multiple therapeutically important genetic aberrations, including frequent aberrations in the FGFR and PI3K pathway genes. Clin Cancer Res; 21(3); 632–41. ©2014 AACR. See related commentary by Krigsfeld and Chung, p. 495

10 October 2008 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
ECEzra E.W. Cohen
Ezra E.W. Cohen
LRLee S. Rosen
Lee S. Rosen
EVEverett E. Vokes
Everett E. Vokes
MKMerrill S. Kies
Merrill S. Kies
AFArlene A. Forastiere
Arlene A. Forastiere
RCRoger B. Cohen
Roger B. Cohen
Purpose: Patients with advanced, incurable thyroid cancer not amenable to surgery or radioactive iodine (131I) therapy have few satisfactory therapeutic options. This multi-institutional study assessed the activity and safety of axitinib, an oral, potent, and selective inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3 in patients with advanced thyroid cancer. Patients and Methods: Patients with thyroid cancer of any histology that was resistant or not appropriate for 131I were enrolled onto a single-arm phase II trial to receive axitinib orally (starting dose, 5 mg twice daily). Objective response rate (ORR) by Response Evaluation Criteria in Solid Tumors was the primary end point. Secondary end points included duration of response, progression-free survival (PFS), overall survival, safety, and modulation of soluble (s) VEGFR. Results: Sixty patients were enrolled. Partial responses were observed in 18 patients, yielding an ORR of 30% (95% CI, 18.9 to 43.2). Stable disease lasting ≥ 16 weeks was reported in another 23 patients (38%). Objective responses were noted in all histologic subtypes. Median PFS was 18.1 months (95% CI, 12.1 to not estimable). Axitinib was generally well tolerated, with the most common grade ≥ 3 treatment-related adverse event being hypertension (n = 7; 12%). Eight patients (13%) discontinued treatment because of adverse events. Axitinib selectively decreased sVEGFR-2 and sVEGFR-3 plasma concentrations versus sKIT, demonstrating its targeting of VEGFR. Conclusion: Axitinib is a selective inhibitor of VEGFR with compelling antitumor activity in all histologic subtypes of advanced thyroid cancer.

22 March 2016 in CA: A Cancer Journal for Clinicians
Verified
Journal Article
Closed access
PDF file
ECEzra E. W. Cohen
Ezra E. W. Cohen
SLSamuel J. LaMonte
Samuel J. LaMonte
NENicole L. Erb
Nicole L. Erb
KBKerry L. Beckman
Kerry L. Beckman
NSNader Sadeghi
Nader Sadeghi
Mandi L. Pratt-ChapmanMandi L. Pratt-Chapman
Mandi L. Pratt-Chapman